Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 6/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | PRF1 | P14222 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511407 | 0.91 | HDAC6 (0.41) | IDH1HDAC6CCR2CRBNPRF1 | |
| SCHEMBL2511462 | 0.88 | CRBN (0.36) | IDH1HDAC6CCR2CRBNPRF1 | |
| SCHEMBL2513409 | 0.85 | HDAC6 (0.39) | IDH1HDAC6CCR2CRBNPRF1 | |
| SCHEMBL2509909 | 0.84 | GAA (0.41) | IDH1HDAC6CCR2CRBNPRF1 | |
| SCHEMBL2505866 | 0.78 | HDAC6 (0.45) | IDH1HDAC6CCR2PRF1BCL6 | |
| SCHEMBL2512874 | 0.78 | HDAC6 (0.39) | IDH1HDAC6CRBNPRF1TP53 | |
| SCHEMBL2511082 | 0.77 | PIK3CA (0.41) | IDH1HDAC6CCR2GAAKDM4E | |
| SCHEMBL18668940 | 0.76 | ALDH1A1 (0.39) | HDAC6TP53GAAMAPTTHRB | |
| SCHEMBL2509721 | 0.76 | HTR4 (0.37) | IDH1HDAC6CRBNPRF1TP53 | |
| SCHEMBL2507370 | 0.76 | IDH1 (0.33) | IDH1CCR2BCL6LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | claimed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | IDH1 1460/4885HDAC6 2366/4885CCR2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.